HK PHARMA<0182> - Results Announcement
Hong Kong Pharmaceutical Holdings Limited announced on 12/12/2000:
(stock code: 182)
Year end date: 31/3/2001
Currency: HKD (Unaudited)
(Unaudited) Last
Current Corresponding
Period Period
from 1/4/2000 from 1/4/1999
to 30/9/2000 to 30/9/1999
('000) ('000)
Turnover : 24,283 11,796
Profit/(Loss) from Operations : (1,543) (4,486)
Finance cost : (2,990) (5,546)
Share of Profit/(Loss) of Associates : - -
Share of Profit/(Loss) of
Jointly Controlled Entities : - -
Profit/(Loss) after Tax & MI : (4,533) (10,058)
% Change over Last Period : N/A
EPS/(LPS)-Basic : (0.46 cent) (9.73 cents)
-Diluted : N/A N/A
Extraordinary (ETD) Gain/(Loss) : - -
Profit/(Loss) after ETD Items : (4,533) (10,058)
Interim Dividend per Share : Nil Nil
(Specify if with other options) : - -
B/C Dates for Interim Dividend : -
Payable Date : -
B/C Dates for (-) General Meeting : -
Other Distribution for Current Period : -
B/C Dates for Other Distribution : -
Remarks:
(1) ACCOUNTING POLICIES
Basis of presentation
The condensed consolidated interim financial statements are prepared in
accordance with Hong Kong Statements of Standard Accounting Practice No.
25 "Interim Financial Reporting". The accounting policies and basis of
preparation used in the preparation of the interim financial statements
are the same as those in the annual financial statements for the year
ended 31 March 2000.
Comparative figures
The presentation of the financial statements have been changed due to the
adoption of the requirements of SSAP 1 (Revised) "Presentation of
financial statements". As a result, the formats of the profit and loss
account and the balance sheet have been revised and in accordance with the
SSAP. Accordingly, certain comparative figures have been reclassified to
conform with the current period's presentation.
(2) LOSS PER SHARE
The calculation of loss per share is based on the net loss from ordinary
activities attributable to shareholders for the period of HK$4,533,000
(1999: loss of HK$10,058,000) and on the weighted average of 986,869,048
(1999: 103,388,173 shares which restated retrospectively as per SSAP5
after the enactment of the share consolidation in the interim period six
months to 30 September 2000) ordinary shares in issue during the Period.
Diluted loss per share for the six months ended 30 September 2000 and 1999
has not been presented as the effect of the assumed conversion of the
share options and the convertible notes of the Company during these period
were anti-dilutive.
(3) DIVIDEND
The directors resolved not to pay an interim dividend to the shareholders
for the six months ended 30 September 2000 (1999: Nil).
|
